Regeneron and its partner Bayer announced a global licensing and settlement agreement with Alvotech on January 29 2026 that resolves all remaining patent disputes surrounding Alvotech’s aflibercept biosimilar to EYLEA. The deal removes the last legal barrier that had delayed the biosimilar’s launch in multiple markets, allowing Alvotech to proceed with commercialization worldwide.
Alvotech’s biosimilar is scheduled to enter the United Kingdom and Canada on January 1 2026, the European Economic Area and other non‑U.S. countries on May 1 2026, and Japan on November 1 2026. The United States launch is slated for the fourth quarter of 2026, pending regulatory approval. The settlement therefore clears the path for a competitive product that will begin to erode EYLEA’s market share in key regions during 2026 and beyond.
For Regeneron, the agreement signals the end of a protracted litigation cycle that had consumed legal resources and created uncertainty for investors. While the company’s flagship drug, EYLEA, has generated billions in annual revenue, the entry of a biosimilar introduces pricing pressure and the potential for a decline in market share. Regeneron has responded by accelerating the launch of EYLEA HD, a higher‑dose, longer‑acting formulation, and by expanding its portfolio with other growth drivers such as Dupixent. The settlement therefore allows Regeneron to reallocate resources from litigation to product development and market expansion.
The broader biosimilar landscape is becoming increasingly crowded, with several companies developing aflibercept alternatives. Regeneron’s strategy of settling with multiple developers—including Sandoz, Formycon, and Celltrion—reflects a proactive approach to managing competitive risk. By resolving disputes early, Regeneron preserves its pricing power and protects its revenue base while maintaining flexibility to invest in next‑generation therapies.
The settlement also underscores the importance of regulatory approvals in the biosimilar market. Alvotech’s biosimilar has already received marketing approval in the European Economic Area, the United Kingdom, and Japan, and the U.S. approval will be a critical milestone for the company’s global growth strategy. For Regeneron, the timing of the settlement aligns with its broader focus on sustaining EYLEA’s dominance in ophthalmology while diversifying its product pipeline.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.